Retinoblastoma Vitreous Seed Clouds (Class 3) A Comparison of Treatment with Ophthalmic Artery Chemosurgery with or without Intravitreous and Periocular Chemotherapy

被引:29
|
作者
Francis, Jasmine H. [1 ,2 ]
Iyer, Saipriya [1 ]
Gobin, Y. Pierre [1 ,3 ]
Brodie, Scott E. [1 ,4 ]
Abramson, David H. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10065 USA
[2] Weill Cornell Med Ctr, Dept Ophthalmol, New York, NY USA
[3] Weill Cornell Med Ctr, Dept Neurosurg, New York, NY USA
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
INTRAARTERIAL CHEMOTHERAPY; INTRAVITREOUS CHEMOTHERAPY; CLASSIFICATION; EYES; MANAGEMENT; MELPHALAN; TOXICITY; OUTCOMES; LECTURE;
D O I
10.1016/j.ophtha.2017.04.010
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To compare the efficacy and toxicity of treating class 3 retinoblastoma vitreous seeds with ophthalmic artery chemosurgery (OAC) alone versus OAC with intravitreous chemotherapy. Design: Retrospective cohort study. Participants: Forty eyes containing clouds (class 3 vitreous seeds) of 40 retinoblastoma patients (19 treated with OAC alone and 21 treated with OAC plus intravitreous and periocular chemotherapy). Methods: Ocular survival, disease-free survival and time to regression of seeds were estimated with Kaplan-Meier estimates. Ocular toxicity was evaluated by clinical findings and electroretinography: 30-Hz flicker responses were compared at baseline and last follow-up visit. Continuous variables were compared with Student t test, and categorical variables were compared with the Fisher exact test. Main Outcome Measures: Ocular survival, disease-free survival, and time to regression of seeds. Results: There were no disease-or treatment-related deaths and no patient demonstrated externalization of tumor or metastatic disease. There was no significant difference in the age, laterality, disease, or disease status (treatment naive vs. previously treated) between the 2 groups. The time to regression of seeds was significantly shorter for eyes treated with OAC plus intravitreous chemotherapy (5.7 months) compared with eyes treated with OAC alone (14.6 months; P < 0.001). The 18-month Kaplan-Meier estimates of disease-free survival were significantly worse for the OAC alone group: 67.1% (95% confidence interval, 40.9%-83.6%) versus 94.1% (95% confidence interval, 65%-99.1%) for the OAC plus intravitreous chemotherapy group (P = 0.05). The 36-month Kaplan-Meier estimates of ocular survival were 83.3% (95% confidence interval, 56.7%-94.3%) for the OAC alone group and 100% for the OAC plus intravitreous chemotherapy group (P = 0.16). The mean change in electroretinography responses was not significantly different between groups, decreasing by 11 mu V for the OAC alone group and 22 mV for the OAC plus intravitreous chemotherapy group (P = 0.4). Conclusions: Treating vitreous seed clouds with OAC and intravitreous and periocular chemotherapy, compared with OAC alone, resulted in a shorter time to regression and was associated with fewer recurrences requiring additional treatment and fewer enucleations. The toxicity to the retina does not seem to be significantly worse in the OAC plus intravitreous chemotherapy group. (C) 2017 by the American Academy of Ophthalmology
引用
收藏
页码:1548 / 1555
页数:8
相关论文
共 3 条
  • [1] A comparison of retinoblastoma vitreous seed clouds (class 3) treated with ophthalmic artery chemosurgery with or without intravitreous chemotherapy
    Francis, Jasmine H.
    Lyer, Saipriya
    Gobin, Pierre
    Marr, Brian
    Brodie, Scott E.
    Abramson, David H.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [2] Superselective Ophthalmic Artery Chemotherapy as Primary Treatment for Retinoblastoma (Chemosurgery)
    Abramson, David H.
    Dunkel, Ira J.
    Brodie, Scott E.
    Marr, Brian
    Gobin, Y. Pierre
    OPHTHALMOLOGY, 2010, 117 (08) : 1623 - 1629
  • [3] Successful Treatment of Massive Choroidal Invasion in Retinoblastoma with Intra-arterial Chemotherapy (Ophthalmic Artery Chemosurgery)
    Abramson, David H.
    Gobin, Y. Pierre
    Dunkel, Ira J.
    Francis, Jasmine H.
    OPHTHALMOLOGY RETINA, 2021, 5 (09): : 936 - +